Tuesday, November 21, 2017

Home Cooking Fires Four Times More Likely on Thanksgiving, But This 'Undervalued' Company Aims to End That

Source: Streetwise Reports   11/21/2017

A company that has a device that prevents home cooking fires has one analyst calling it an "undervalued and underfollowed play on new safety requirements."

As families and friends gather to celebrate Thanksgiving this year, remember to exercise caution when cooking because Thanksgiving is the most dangerous day for cooking fires, followed by the day before Thanksgiving, Christmas and Easter, according to the National Fire Protection Association (NFPA). While cooking fire is always a risk, it is especially so during the holidays.

Cooking equipment, reported the NFPA, "was involved in almost half of reported home fires and home fire injuries." Cooking fire is the leading cause of household fire across North America. It is the leading cause of fire injuries and results in more than $1 billion in direct property damage each year.

Pioneering Technology Corp. (PTE:TSX.V) is working to solve the issue of cooking fires. It owns disruptive technology and products that are designed to help stop cooking fires from happening in the first place. Since 2008, its patented temperature limiting control technology has been installed in more than 250,000 households across North America without a single cooking fire being reported. From 2013 through 2016, Pioneering Technology has had a compound annual growth rate of 69%.

Pioneering Technology's SmartBurner already meets a new UL 858 standard for cooking fire prevention that will become mandatory for all electric stoves in April 2019.

In October, Pioneering announced the completion of largest purchase to date, for about 20,000 four-burner SmartBurner kits from one of North America's largest suite-hotel companies. The company stated that this hotel chain has now "ordered and installed SmartBurner in approximately 74,000 hotel rooms in more than 600 of its hotel properties."

Analyst Russell Stanley with Echelon Wealth Partners, in an Oct. 4 report, stated that the firm continues "to view PTE as an undervalued, underfollowed play on new safety requirements that should drive strong demand growth for the company's cooking fire prevention products."

He views the completion of the hotel order "positively as it reflects strong follow on demand from the hotel chain market. . .This market segment (hotel/motel chains and corporate housing with fully-equipped kitchens) represents an attractive market opportunity for Pioneering, and we expect the Company to pursue additional customers in this space."

Echelon has a Speculative Buy recommendation on Pioneering and a 12-month target price of $1.60 per share. The stock is currently trading at $0.71.

Nick Hodge, writing on Oct. 5 in Early Advantage, noted that "revenue for 2017 is on a C$10 million run rate. So far this year sales are 71% higher than at the same point in 2016."

Hodge explained that "less than 1% of the existing electric coil stoves in North America have been retrofitted. So many orders are still to come, in my opinion. Equally as exciting are the new UL stove standards that go into effect in April 2019. To pass, a pot of oil is placed on the stove and the burner turned to high. If the oil ignites within 30 minutes, the stove fails. If it doesn't catch fire, the stove passes. Pioneering remains the only company that can pass this test."

"April 2019 is right around the corner," Hodge noted. If the major appliance manufacturers "want to meet the new standard in time, they are going to have to act soon. Pioneering's technology being incorporated into new stoves on the factory floor becomes likelier and likelier with each passing day." Hodge wrote that the stock "is a buy under $1.10."

Technical analyst Clive Maund of CliveMaund.com noted in May that Pioneering has "developed a unique technology around cooking implements and equipment that prevents kitchen fires, the biggest cause of home fires, and thus promises to save insurance companies billions of dollars. This technology is in its way as revolutionary as catalytic converters were for the auto industry many years ago, which at a stroke largely eliminated the smog problem in Los Angeles and other big cities, and there is a good chance that the government will mandate the use of the company's products—if that happens this stock will go ballistic."

Want to read more Streetwise Reports articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see a list of recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She owns, or members of her immediate household or family own, securities of the following companies mentioned in this article: None. She is, or members of her immediate household or family are, paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Pioneering Technology Corp., a company mentioned in this article.

Additional disclosures about the sources cited in this article

( Companies Mentioned: PTE:TSX.V, )



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/article/2017/11/21/home-cooking-fires-four-times-more-likely-on-thanksgiving-but-this-undervalued-company-aims-to-end-that.html

Cobalt Pure-Play Hitched to Electric Vehicle Boom

Source: Streetwise Reports   11/21/2017

Forecasts of an electric vehicle boom are behind skyrocketing demand for cobalt, a major component in batteries. In this interview with The Energy Report, Anthony Milewski, CEO of Cobalt 27 Capital Corp., discusses the company's unique position as a two-pronged pure-play on cobalt.

The Energy Report: Would you bring us up to date on what's happening in the cobalt market?

Anthony Milewski: A few weeks ago was LME Week in London, which is the annual gathering of producers and consumers for not just cobalt but for a variety of base metals. It's an international gathering with people from all over the world—China, United States, Europe, Africa.

And I would say that it's really the mating season for cobalt. What that means is cobalt contracts are typically 12-months long, although there's a lot of variation. Many of the next 12 months of contracts are set during this week or discussed, if not signed. It's a major week for the consumers and producers to get together and have a meeting of the minds around what the next 12 months will look like for cobalt.

TER: What was the outcome of these meetings?

AM: The first takeaway is that there's tremendous new demand coming into the market because of the electric vehicle. All of the talk and all the meetings I was in was around the impact of electric vehicle sales and penetration on the cobalt market.

A second conversation that's going on is about future supply, security of supply, where does supply come from to meet that new demand that's coming into the market and going to come in large quantities in future years.

And then, finally, the questions are really about ethical sourcing out of the Congo and making sure that conflict cobalt doesn't make its way into the value chain. Not all cobalt is sourced equal out of the Congo. You have first-tier producers like Glencore International Plc (GLEN:LSE) that produce a high-quality, trustworthy material. The issues associated with conflict cobalt are more focused around individuals, artisanal mining and some of the related problems.

TER: Let's talk about your first point, how cobalt is tied to electric vehicles. Is the growth of electric vehicles the main factor behind the projected demand growth for cobalt?

AM: The market, until recently, was seeing modest growth. The superalloy industries, which are jet engines, were seeing 7–8% year-on-year growth. But because of electric vehicles over the last few years, we saw a twinkling of what the future of cobalt might look like. To put it in perspective, the market today has 100,000 metric tons (100,000 mt). If you believe the consensus view of electric vehicle penetration in 2025, which is 8–12%—that's the banded range from Wall Street today—we're going to need something like 200,000 mt of cobalt with 100% of that going into the electric vehicle market. In other words, the newfound demand is tremendous, and it's going to materially impact the industry.

Now, there's a lot of discussion about battery chemistry changes and some things that will make it a little bit more achievable. But on its face, we are seeing a tremendous impact on the industry from the adoption and sales of electric vehicles.

TER: Would you tell us about what's happening with electric vehicles batteries, how the movement in China is away from the lithium ion phosphate (LFP) battery to the nickel manganese cobalt (NMC) battery and what that means for cobalt?

AM: This is really about range. These LFP batteries, depending on the battery, were doing 30, 40, 50 miles; the range was tiny. The NMC battery is an energy-dense battery that can go, in some cases, over 400 miles. So that switch is really about what the consumers' preferences are, and the consumers' preference is a car that can basically go anywhere that a person goes in a single day. Remember, the overwhelming majority of commuters globally do not travel now in a day more miles than a single charge of a modern electric vehicle battery.

That switch was driven as a way of extending the range of these vehicles and was critical and is probably going to accelerate the adoption of the electric vehicle as it becomes a tool that doesn't really change your life. In other words, with any electric vehicle, you fill it up when you're sleeping at night. It's not impacting you because the range is sufficient for your daily needs. In fact, you could go a couple of days without charging it.

TER: And the NMC battery uses a good amount of cobalt?

AM: There are two basic formulations today in the market. There's an NMC, which is what most of the market uses, and there's the NCA, nickel-cobalt-aluminum, the preferred battery by Tesla Motors Inc. (TSLA:NASDAQ). The cobalt content in those batteries varies based on factors when you have cobalt in a given battery. If you think about a battery, think about an engine. Do you have a V-6 or a V-8 or do you have a turbo? There are different sizes and energy densities in batteries.

But the important factor here is the ratio. The current nickel-manganese-cobalt, which is the most common battery, is 6:2:2: 6 parts nickel, 2 manganese, 2 cobalt. The next generation of battery, which is probably two to four years away is 8:1:1, 8 nickel, 1 manganese, 1 cobalt. Those are the two primary chemistries that you will see in the coming year.

TER: I'd like to go back to something that you touched on a little bit earlier, which is about the security of supply. What's happening with the supply of cobalt in the world and Congo sourcing and what does that means for Cobalt 27 Capital Corp. (KBLT:TSX.V; CBLLF:OTC; 27O:FSE)?

AM: The key point about the Congo is ensuring that the material that goes into your electric vehicle or even your cellphone, which has a significant amount of cobalt relative to the size of the battery in it, is ethically sourced from the Congo. Over half of the world's cobalt comes out of the Congo. And so, the conversations are around how you do that.

If you're buying from a large producer, like a Glencore, there's no problem there. Where you run into problems are the allegations around certain Chinese companies taking artisanal material that ultimately ends up in batteries.

The industry is really responding and taking steps toward blocking this. One of the things I see, and I've seen it now over the last year to two years, is each of the major automakers actually have one or two individuals whose full-time job is to ensure a secure supply chain and to do everything they can to keep that material from entering the battery supply chain.

It's interesting to point out that automakers aren't making the batteries. Companies like Panasonic Corp. (6752:TYO) are making the batteries that go into the automobile, but still, the automobile company that's ultimately going to sell you the car is taking the onus of trying to prevent this material from entering the supply chain. I think the battery makers are doing it as well, as are people on the ground in the Congo. We're seeing an industry making an effort to combat this.

TER: Let's talk about Cobalt 27. The company began trading on the TSX Venture Exchange in June. Can you tell us about the genesis of the company?

AM: Having experienced the uranium bull market—and uranium, which is completely different but it shares some qualities, namely that it was hard to invest directly into the physical commodity—and having had that experience of scarcity of supply, it got me thinking about how you would invest in cobalt.

We looked at the electric vehicle. A couple years ago we took the view that this was going to be mass adopted, and that we needed to understand how it was going to impact basic materials. But we also understand that the impact on the given basic material takes place at a varied penetration rate. What I mean is electric vehicles are ultimately going to impact copper but not for five or six more years when the number of vehicles really compounds.

However, on the other end of spectrum, for cobalt, the impact is going to be immediate and exponential as we go forward. We understood that and wanted to find out how we could play cobalt. What we realized immediately was there was no way to play. There are certain large-cap companies that have a small percentage of their EBITDA as a function of selling cobalt. That didn't work. The exploration companies by and large didn't meet our risk profile, namely the binary outcome risk of exploration.

And so what I wanted to do was marry a Uranium Participation Corp. (U:TSX)-type vehicle with the financial innovation of a Wheaton Precious Metals Corp. (WPM:TSX; WPM:NYSE); in other words, create a hybrid that was underpinned by physical cobalt and have the growth come from large streaming transactions.

TER: You currently own 2,000 tonnes of physical cobalt and a portfolio of cobalt royalties, correct?

AM: We own 2,160 tonnes of cobalt, making it what we believe is the largest position in the world except for the Chinese strategic government supply. We have a handful of royalties. I look at them as options. They're deep out of the money options. We have a growth strategy that's focused on large streaming transactions.

TER: Would you tell us about the royalty and streams that you already have and how you're looking ahead to getting new ones?

AM: The royalties and streams that we have today are on early-stage projects, which are options. But the strategy going forward, and where we're spending our time and effort today, is on large, producing assets, long-life assets that are producing cobalt today that will be material streams for the company going forward and add market cap and add balance sheet to the company. The company is focused on executing the business plan, and our business plan includes streaming transactions.

TER: In June, when you went public, you completed a $200 million public offering. You've recently filed a $300 million shelf prospectus. Would you explain what that is?

AM: As just indicated, our strategy is a growth strategy. With any growth strategy, you need to raise capital. A responsible capital structure includes a shelf, which allows you to act quickly when opportunities arise. That shelf is in place so that the company is able to quickly act on any streaming transaction which, at some future date, hopefully comes to fruition.

TER: Please tell us about Cobalt 27's senior management team.

AM: Justin Cochrane is the president and COO. He's been in streaming since its advent, since streaming transitioned away from royalties. He spent a decade at an investment bank in Canada and then later ran Sandstorm Gold Ltd.'s (SSL:TSX; SAND:NYSE.MKT) business development, corporate development group; Sandstorm being a streaming and royalty company. He's transacted on something like 40 or 50 streams and royalties, a material dollar amount as well. He's widely regarded as an expert in the field, and he's a tremendous value to the team.

Nick French is a company director. He is probably one of the preeminent cobalt traders known globally for the last 20 years. He has deep insight into the markets and into the trading environment.

I am the chairman and CEO. I've spent my career in mining funds. I think the value add for myself is having worked across a large number of transactions. I'm able to create shareholder value through my investment skills.

I'll just quickly highlight that we have a fully independent board. One of our board members, Frank Estergaard, is a 37-year partner at KPMG. We have other people like John Kanellitsas from Lithium Americas Corp. (LAC:TSX; LHMAF:OTCQX), Jon Hykawy, a well-regarded and known analyst, and Nick French is another director.

We also have a very sophisticated advisory board, which includes Dr. Prabhakar Patil, the former CEO of LG Chem Ltd. (051910:KSE; 051915:KSE; LGCLF:OTCPK), as well as Ted Miller, a senior member of Ford Motor Co.'s (F:NYSE) battery team. We've tried to pull together top individuals across the battery value chain such that if we have a question about a nickel laterite deposit because cobalt is often a byproduct of nickel lateralite, we'll ask Phil Day. He's regarded widely as an expert in nickel, and he sits on our advisory board. If someone asks me a question about a battery, I ask Dr. Patel. He's one of the original people working on this for LG Chem. We've tried to put together a very experienced group of individuals around the management team to augment our knowledge.

TER: Are there catalysts in the short or medium term that investors should look out for?

AM: I would look out for cobalt prices. Watch what the big automobile companies are doing. Look at all the announcements around the model commitments and sales numbers of electric vehicles because that's a leading indicator to a move in cobalt. You could have some alpha by watching that because that might happen before the move in cobalt price. The reason I say that is because when you see the cobalt price moving, ultimately that's going to impact our share price, and you're going to see us go up. So if you have any insights that help you take a position on what's going to happen with the electric vehicle adoption rate, if that's going to accelerate, then that will give you a basis to have a view around the cobalt market, which ultimately will be a knock-on effect into our stock.

TER: Thanks for your time, Anthony.

Anthony Milewski, chairman, CEO and a director of Cobalt 27 Capital Corp., has spent his career in various aspects of the mining industry, including as a company director, advisor, founder and investor. In particular, he has been active in the battery metals industry including investing in cobalt and actively trading physical cobalt. In 2016, The Mining Journal named him a Future Mining Leader.

Want to read more Energy Report interviews and articles? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see a list of recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Patrice Fusillo conducted this interview for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She owns, or members of her immediate household or family own, shares of the following companies mentioned in this article: None. She is, or members of her immediate household or family are, paid by the following companies mentioned in this article: None.
2) Cobalt 27 Capital Corp. is a billboard sponsor of Streetwise Reports. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclaimers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Cobalt 27 Capital Corp. had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Anthony Milewski and not of Streetwise Reports or its officers.
4) Anthony Milewski: I was not paid by Streetwise Reports to participate in this interview. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview. I own shares of the following companies mentioned in this interview: Cobalt 27 Capital Corp.
5) Interviews are edited for clarity. Streetwise Reports does not make editorial comments or change experts' statements without their consent.
6) This interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
7) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

( Companies Mentioned: KBLT:TSX.V; CBLLF:OTC; 27O:FSE, )



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/article/2017/11/21/cobalt-pure-play-hitched-to-electric-vehicle-boom.html

Expert's Opinion: 'Back Up the Truck' for this Stock

Source: Ron Struthers for Streetwise Reports   11/21/2017

Ron Struthers of Struthers' Resource Stock Report takes a look at results from two mining companies, and picks the one he considers a winner.

I think a comparison of Garibaldi Resources Corp. (GGI:TSX.V) and Silver Bull Resources Inc. (SVB:TSX; SVBL:NYSE.MKT) would be a very good exercise. Both are hitting some high-grade sulphides: Garibaldi, nickel and copper with precious metals; and Silver Bull, zinc and lead with silver.

GGI had a high-grade intersect of 7.2% nickel and 3.4% copper over 4.8 meters with 0.82 g/t palladium, 0.78 g/t platinum, 0.40 g/t Au, 10 g/t Ag and 0.195% cobalt. Based on current metal prices that 4.8 meters by GGI is worth around $1,018 per ton.

SVB hit 9 meters @ 20.7% zinc, 1.0% lead, 98 g/t silver and 0.26% copper including 3.65 meters @ 47.8% zinc, 2.5% lead, 105 g/t silver and 0.26% copper from 3.55 meters to 7.2 meters. Based on current metal prices that 3.65 meters by SVB is worth around $1,498 per ton.

So on yesterday's drill results the Silver Bull intersect is worth about 50% more than GGI's intersect, but GGI is valued 1,200% higher, or 13 times. If you own GGI and not SVB it is obvious what to do. Regardless this exercise points out the extreme undervaluation of SVB, and I am not factoring the deposit SVB already has.

GGI market cap: 96.7 X $3.80 = $367 million

SVB market cap: 199 X $0.14 = $28 million

Garibaldi (recent price $3.80; entry price $0.21) Opinion: Hold

GGI put out news Nov. 20 that drill hole 17 has hit a new zone of mineralization and the company released the assay results for the first four holes. Although it hit some good grades and decent widths I believe the stock was pricing in much longer intercepts. We have already taken out good profits so I am content to hold the rest longer term.

Hole 4 had a high-grade 7.2% nickel and 3.4% copper over 4.8 meters within a 48.2-meter interval grading 1.1% nickel and 0.69% copper. Hole 3 hit 13.5 meters of 1.05% nickel and 1.0% copper. Hole 2 hit 18 meters of 0.69% nickel and 0,80% copper. Hole 1 hit 60.5 meters of 0.54% nickel and 0.53% copper.

These are some good results but nothing compared to Voiseys Bay, and I am sure the stock price was looking for much more. The company is also hitting gold, platinum and palladium. There are plenty more results to come and we will get a better idea of this discovery in time. For now I will watch the stock price and may suggest buying some position back if it gets low enough.

Otherwise hold remaining positions. The stock opened strong, going above $5 and then some reality sunk in.

From the company news release:

Fourteen holes over 3,671 meters have been completed to date (new photos, maps and an updated presentation will be posted soon at GaribaldiResources.com). EL-17-04 cut 7.2% nickel, 3.4% copper, 0.82 g/t palladium, 0.78 g/t platinum, 0.40 g/t Au, 10 g/t Ag and 0.195% cobalt over 4.8 meters at the bottom of a broader 48.2-meter interval from 108.4 meters grading 1.1% nickel, 0.69% copper, 0.38 g/t palladium, 0.23 g/t platinum, 0.16 g/t Au, 3.1 g/t Ag and 0.032% cobalt;

• EL-17-04 also intersected a second zone of mineralization within a variable-textured gabbro featuring 1.08% nickel and 0.68% copper over 12 meters starting at a depth of 189 meters;

• EL-17-03, cutting across part of the historic northwest zone, intersected 13.5 meters grading 1.05% nickel and 1.0% copper within a broader core interval of 39 meters featuring 0.91% nickel and 0.74% copper beginning at a depth of 42 meters;

• EL-17-02 intersected broad core intervals of disseminated sulphide mineralization between a depth of 58.5 meters and 190.5 meters. Significant intercepts included 18 meters @ 0.69% nickel and 0.80% copper, and 24 meters @ 0.56% nickel and 0.65% copper. The hole was drilled toward the east into a previously untested area. Valuable data was generated from the downhole probe;

• EL-17-01 was drilled away from the historic northwest zone toward the untested east, providing the best platform to collect important data from the downhole probe. Encouragingly, the hole intersected two long core intervals of disseminated sulphide mineralization totaling 176 meters to a depth of 332 meters, highlighted by a 60.5-meter section grading 0.54% nickel and 0.53% copper. Higher grades of copper (0.80%), palladium (1.26 g/t), platinum (0.60 g/t) and gold (0.60 g/t) were intersected over 4.5 meters.

The best positive factor that the market probably likes is that the high-grade intersect in hole 4 was at the bottom so it probably continues deeper.

There are a few observations on the chart. There is a triple top around $5 and that will now be very difficult to overcome. Quite possibly a significant correction might take grip. Support is around $3.30, and if the stock falls below that it will probably trade down to around $2 and fill the gap between $2.20 and $3.20.

strutherschart11-21

Silver Bull (recent price $0.14; entry price $0.12) Opinion: Strong buy; back up the truck.

Everyone should own a position in this stock before the market catches on to this. There was a $0.08 financing; most of that (18 million shares) became free trading last week and that might be some of the pressure holding the stock back. I believe it is not very wise to be a seller here, but some just see a good profit, take it and run?

The Nov. 20 press release headline reads: Silver Bull intersected 9 meters of sulphide mineralization grading 20.7% zinc, 1% lead and 98 g/t silver, including 3.65 meters of massive sulphide mineralization grading 47.8% zinc, 2.5% lead and 105 g/t silver on its Sierra Mojada project in Coahuila, Mexico. SVB is hitting better numbers than Garibaldi; the stock is a steal here. Zinc is not priced as high as nickel, but the SVB zinc grades are much higher—and so are the precious metals, because the silver grades so high; 537 g/t silver is like 10 g/t gold.

Highlights from the four holes announced in this news release include:

Hole T17010: 9 meters @ 20.7% zinc, 1.0% lead, 98 g/t silver and 0.26% copper including 3.65 meters @ 47.8% zinc, 2.5% lead, 105 g/t silver and 0.26% copper from 3.55 meters to 7.2 meters.

Hole T17009: 3 meters @ 537 g/t silver, 3.9% zinc and 1.06% copper including 1 meter @ 1,280 g/t silver, 14.8% zinc and 2.3% copper from 0 meters to 1 meter.

Holes 7 and 8 had no significant hits.

This drilling was on the second of three sulphide structures that Silver Bull has identified, and this second one seems more dominant in zinc compared to copper in the first structure.

Tim Barry, president, CEO and director of Silver Bull states, "We are extremely pleased with the results from this batch of drill core. The new sulphide zone is proving to be very productive for high grade sulphide mineralization. The drilling summarized in this news release targeted the second of three steeply dipping, discreet structures we have identified in the sulphide zone. Drilling from the first structure previously announced in the news releases of holes T17001 to T17006 was dominated by high grade silver-copper sulphide mineralization grading up 1,300g/t silver and 6% copper. This second structure is dominated by extremely high zinc sulphide mineralization, grading up to 48% zinc and suggests a metal zonation in the mineralization we see at Sierra Mojada and provides very useful information in helping us vector into an intrusion, interpreted as the source of metals currently defined on the project. In addition to vectoring in on an intrusive source we can now project the mineralization we are currently drilling into the extensive channel sampling and drilling completed at the eastern end of the deposit and show a target over 3 kilometers in strike length. When you consider this, coupled with the fact we have identified three structures in this east-west trend similar in style, dip and grade of mineralization, we see some very significant immediate targets at Sierra Mojada. In addition to the drilling, work is currently underway to access some of the underground workings further east to confirm the style of mineralization."

Ron Struthers founded Struthers' Resource Stock Report 23 years ago. The report covers senior and junior companies with ample trading liquidity. He started his Millennium Index of dividend stocks in 2003 - $1,000 invested then was worth over $4,000 end of 2014 and the index returned 26.8% in 2016. He retired from IBM after 30 years in customer service, systems and business analyst, also developing his own charting software. He has expertise in junior start-ups and was a co-founder of Paramount Gold and Silver.

 

Want to read more Gold Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see a list of recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

 

Disclosure:
1) Ron Struthers: I, or members of my immediate household or family, own shares of the following companies mentioned in this article: Silver Bull Resources and Garibaldi Resources. I personally am, or members of my immediate household or family are, paid by the following companies mentioned in this article: None. My company currently has a financial relationship with the following companies mentioned in this article: Silver Bull Resources. I determined which companies would be included in this article based on my research and understanding of the sector.
2) The following companies mentioned in this article are sponsors of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article.
4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Smartcool Systems and NeutriSci International, companies mentioned in this article.

Charts and images provided by the author.

Struther's Resource Stock Report Disclaimer:
All forecasts and recommendations are based on opinion. Markets change direction with consensus beliefs, which may change at any time and without notice. The author/publisher of this publication has taken every precaution to provide the most accurate information possible. The information & data were obtained from sources believed to be reliable, but because the information & data source are beyond the author's control, no representation or guarantee is made that it is complete or accurate. The reader accepts information on the condition that errors or omissions shall not be made the basis for any claim, demand or cause for action. Because of the ever-changing nature of information & statistics the author/publisher strongly encourages the reader to communicate directly with the company and/or with their personal investment adviser to obtain up to date information. Past results are not necessarily indicative of future results. Any statements non-factual in nature constitute only current opinions, which are subject to change. The author/publisher may or may not have a position in the securities and/or options relating thereto, & may make purchases and/or sales of these securities relating thereto from time to time in the open market or otherwise. Neither the information, nor opinions expressed, shall be construed as a solicitation to buy or sell any stock, futures or options contract mentioned herein. The author/publisher of this letter is not a qualified financial adviser & is not acting as such in this publication.

( Companies Mentioned: GGI:TSX.V, SVB:TSX; SVBL:NYSE.MKT, )



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/article/2017/11/21/expert-opinion-back-up-the-truck-for-this-stock.html

Consumer Demand for 'Green' Packaging Driving This Company's Rapid Growth

Source: Streetwise Reports   11/21/2017

A Vancouver-based company is making its mark on the rapidly expanding bioplastics sector.

As more and more consumers are becoming aware of the potentially negative health impacts of chemicals in plastics, they are demanding cleaner packaging and a move away from petroleum-based plastics. Bioplastics have become the fastest growing segment in the plastics industry.

The global bioplastics market is predicted to grow at a compound annual growth rate of 29% by 2020, according to market research firm Technavio.

One company leading the charge is Good Natured Products Inc. (GDNP:TSX.V), which changed its name from Solegear Bioplastic Technologies Inc. and began trading Oct. 31 on the TSX Venture Exchange under the new ticker GDNP.

The Vancouver-based company has developed a wide array of products, including more than 130 plant-based products and packaging items consisting of over 100 food packaging products and over 30 home and business organization products.

Good Natured noted that macro trends should "continue to drive demand for alternatives to petroleum-based plastics—regulatory pressure, consumer demand for products that are free from hazardous chemicals, corporate sustainability objectives to reduce reliance on fossil fuels, and increased attention on overall food safety and packaging materials."

The company stated that it expects "revenues for the fiscal year ending Feb. 28, 2018, to grow by 50% year over year to approximately $3.1 million."

Good Natured also noted that it has a "strong pipeline of new products under development that include: items targeting the replacement of polystyrene, home organizational totes and crates (which represent 35 per cent of a $16-billion (U.S.) market), and fresh prepared and ready-made meal packaging, which has experienced growth of 30 per cent since 2012."

The company sells to 70 customers across 20 states and provinces. Its customers include national, regional and small business retailers, food producers and packaging distributors.

The rapid growth in the bioplastic industry has, according to the company, created "a highly fragmented emerging industry of new entrants, longer-standing bioplastic companies and divisions of larger organizations. This presents significant consolidation opportunities that the company aims to pursue, creating an opportunity for further growth through strategic acquisitions that bring a new customer base, advanced intellectual property and/or an expanded product assortment, all of which enhance the company's dual-strategy approach."

Good Natured announced the acquisition of Lindar Corp.'s bioplastic division last December. "The company anticipates the completion of an outsourced supply chain, fulfilment and warehousing agreement with Lindar by the end of the calendar year."

The company has caught the attention of newsletter writer Alex Koyfman, who noted on Sept. 1 article in Penny Stock Millionaire newsletter that Good Natured, then known as Solegear, "is a next-generation bioplastic engineering firm dedicated to fundamentally changing the way plastics are made. The company custom engineers, produces, and distributes bioplastic products and packaging with some of the highest percentages of renewable, plant-based materials currently available in the industry."

"With 22x growth registered between 2016 and 2017," Koyfman stated, "Solegear has clearly crossed a major milestone and moved on towards developing its client list, not just its product line. . .with the list of major corporations now buying its product, the big picture is quite impressive."

The company is led by an experienced management team. CEO Paul Antoniadis is a founding partner at Scenario Ventures and is the former CEO of Best Buy Europe. Board chairman Salil Munjal is the managing partner at Yaletown Venture Partners.

Good Natured has about 91.5 million shares outstanding, of which 43% are owned by management and insiders. The company's market cap is approximately CA$8.1 million.

Want to read more Streetwise Reports articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see a list of recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She owns, or members of her immediate household or family own, securities of the following companies mentioned in this article: None. She is, or members of her immediate household or family are, paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Good Natured Products Inc., a company mentioned in this article.

Additional disclosures about the sources cited in this article

( Companies Mentioned: GDNP:TSX.V, )



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/article/2017/11/21/consumer-demand-for-green-packaging-driving-this-companys-rapid-growth.html

'Hot' Alzheimer's Market is Promising for Biotech with 'Novel' Drug Candidate

Source: Streetwise Reports   11/20/2017

André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's drug developer.

In a Nov. 13, 2017 research note, analyst André Uddin with Mackie Research Capital Corp. reported that, as expected, ProMIS Neurosciences Inc. (PMN:TSX) announced $0 revenue for Q3/17. Fully diluted earnings per share was ($0.01), which was in line with Mackie's estimate. At the quarter's end, the biotech had CA$3.3 million in cash and no debt. "Financials are less important as ProMIS is still a preclinical biotech company," wrote Uddin regarding the Q3/17 results.

ProMis, Uddin continued, is developing PMN310 as a "novel Alzheimer's drug candidate based on a new amyloid beta theory—the disease is mainly caused by soluble toxic amyloid beta oligomers."

Mackie expects at least two upcoming catalysts for ProMIS. One is that the firm expects ProMIS "to disclose more preclinical results that should demonstrate a better efficacy and safety profile of PMN310 than Biogen's aducanumab," Uddin stated.

The second is that positive PMN310 clinical data will spur a collaborative deal, perhaps as early as next year. "We have assumed ProMIS to outlicense PMN310 in 2019 for an upfront payment of CA$50M; our numbers are likely conservative," said Uddin.

This compares to the US$205 million that AbbVie Inc. (ABBV:NYSE) paid upfront in October to license a preclinical Alzheimer's drug candidate from Alector LLC (private). Similarly, Biogen Inc. (BIIB:NASDAQ) recently committed an additional US$500 million to its Phase 3 Alzheimer's drug candidate aducanumab.

Mackie is maintaining its Speculative Buy rating and CA$0.50 per share target price on ProMIS, whose stock is currently trading at around CA$0.23 per share.

Want to read more Life Sciences Report articles like this? Sign up at www.streetwisereports.com/get-news for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Additional disclosures about the sources cited in this article

( Companies Mentioned: PMN:TSX, )



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/article/2017/11/20/hot-alzheimers-market-is-promising-for-biotech-with-novel-drug-candidate.html

Maxim's Target Price on Biotech Makes It More Than a Tenbagger

Source: Streetwise Reports   11/20/2017

Jason Kolbert, an analyst with Maxim Group, provided an update on this biopharmaceutical firm's two recently acquired oncology assets.

Cytori Therapeutics Inc. (CYTX:NASDAQ) recently showed bioequivalence of late-stage ATI-0918, its generic liposomal formulation of doxorubicin, to Johnson & Johnson's Caelyx, which is a branded product in the European Union, Maxim's Jason Kolbert reported in a Nov. 16 research note. Cytori presented the supporting data at the annual meeting of the 2017 American Association of Pharmaceutical Scientists held Nov. 12 to 15.

The bioequivalence for Cytori's ATI-0918 is about 90% of doxorubicin, "which is very good," noted Kolbert. In comparison, generics must fall within 80–125% bioequivalence of the reference product, and the closer to 100%, the better. This confidence interval is characteristic of generics with which regulators are concerned.

About these findings, Kolbert said they "should be very attractive to potential partners." In fact, Maxim Group anticipates that Cytori will pursue a partnership to commercialize ATI-0918.

The biotech is expected to file in H2/18 for approval of this nanomedicine from the European Medicines Agency, and subsequently do the same for ATI-1123, its patented, nanoparticle-stabilized liposomal formulation of docetaxel. "These products both represent significant upside to the Cytori story, neither of which is, in our opinion, being reflected in the current 'distressed' value of the company," wrote Kolbert.

ATI-0918 and ATI-1123 are assets that Cytori gained when it acquired Azaya Therapeutics. "Both represent low-risk, high-reward specialty pharma products that, if monetized, could generate nondilutive capital for the company," Kolbert indicated.

In light of the transaction with Azaya, which closed in Q1/17, Kolbert estimates "a 15% market share and 35% royalty rate for the $300 million European liposomal doxorubicin market with the first year of commercial sales in 2019," he said. To be conservative, Kolbert excludes from his model on Cytori projected revenues from the United States or any other potential market.

Maxim Group has a Buy rating and a $5 per share 12-month target price on Cytori, whose stock is now trading at around $0.38 per share.

Want to read more Life Sciences Report articles like this? Sign up at www.streetwisereports.com/get-news for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Additional disclosures about the sources cited in this article

( Companies Mentioned: CYTX:NASDAQ, )



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/article/2017/11/20/maxims-target-price-on-biotech-makes-it-more-than-a-tenbagger.html

Stock Price Jump Reflects Biotech's Active October

Source: Streetwise Reports>   11/20/2017

This immunotherapy firm's stock recently doubled its Nov. 7 price following lots of news, including a clinical data release, a trial launch and an executive appointment.

The series of recent catalysts for OncoSec Medical Inc. (ONCS:NASDAQ) includes its release of "positive long-term follow-up data," noted Ram Selvaraju, an analyst with H. C. Wainwright & Co. These results were from its Phase 2 OMS I-102 study, in which the immune stimulator ImmunoPulse IL-12 (pIL-12) was given in combination with Keytruda (pembrolizumab) to 11 melanoma patients unlikely to respond to anti-PD-1 therapy.

The results showed a progression-free survival rate of 57% at 15 months, and all 11 patients achieved duration of response. These data, together with the previously reported best overall response rate of 50% at 24 weeks, suggest "the combo therapy can prime a coordinated innate and adaptive immune response, which could then lead to improved clinical outcomes in patients not responsive to anti-PD-1 therapy alone, in our view," Selvaraju wrote.

The analyst added that these data also "bode well" for OncoSec's PISCES/KEYNOTE-695 Phase 2b trial, which it initiated in October. In that study, the same combination of therapies will be administered—ImmunoPulse plus Keytruda—but in a different patient population. These patients have unresectable metastatic melanoma and have progressed or are progressing on an anti-PD-1 therapy. Enrollment of the 48 patients will take place in the United States and Australia, and will be divided into two cohorts, 23 in the first, 25 in the second.

The clinical trial's primary endpoint is the best overall response rate at 24 weeks. Management has indicated an overall response rate of 30% "would be considered a success for this study," Selvaraju said. "We believe preliminary interim data could be reported around mid-2018."

If positive, those interim data "may allow the company to apply for breakthrough therapy designation for pIL-12 in patients who have failed anti-PD-1 monotherapies," Selvaraju explained.

He reiterated that ImmunoPulse IL-2 has both fast track and orphan status designations. Were the FDA to approve it, and were it to be brought to market, he added, "we note that 5,000–10,000 patients on an annual basis may benefit from this combo therapy with improved response rates."

Also in October, OncoSec "closed on two registered direct offerings" that yielded $8.2 million at about $1.34 per share, reported Selvaraju.

Finally, the biotech, in early November, appointed Daniel O'Connor as its CEO. "Mr. O'Connor's expertise in the biotech industry, particularly with regard to areas involving the overlap between immunology and oncology, should serve OncoSec well," Selvaraju concluded. Most recently, O'Connor was the CEO of Advaxis Inc. (ADXS:OTCBB), also an immuno-oncology company. Prior to that, he worked at ImClone Systems from 2003 to 2008, at which point it was sold to Eli Lilly. There, as senior vice president, general counsel and secretary, he supported the clinical development, launch and commercialization of Erbitux, among other accomplishments.

H.C. Wainwright & Co. maintains its Buy recommendation and $6 per share price target on OncoSec, whose shares are currently trading at around $2.08.

Want to read more Life Sciences Report articles like this? Sign up at www.streetwisereports.com/get-news for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Additional disclosures about the sources cited in this article

( Companies Mentioned: ONCS:NASDAQ, )



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/article/2017/11/20/stock-price-jump-reflects-biotechs-active-october.html